期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 54, 期 15, 页码 5607-5611出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm200644r
关键词
-
资金
- NNSF [20721003]
- CAS [KSCX2-YW-R-168, KSCX2-YW-R-208]
- Shanghai ST Foundation [09540703900]
- National Science & Technology Major Project [2009ZX09301-001, 2009ZX09102-056]
- MOST [2010DFB73280]
- State Key Laboratory of Drug Research [SIMM1106KF-05]
- Natural Science Foundation of Shanghai [11ZR1408700]
For proof-of-concept of halogen bonding in drug design, a series of halogenated compounds were designed based on a lead structure as new inhibitors of phosphodiesterase type S. Bioassay results revealed a good correlation between the measured bioactivity and the calculated halogen bond energy. Our X-ray crystal structures verified the existence of the predicted halogen bonds, demonstrating that the halogen bond is an applicable tool in drug design and should be routinely considered in lead optimization.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据